Amerikanische Gesellschaft für Hirudotherapie

Protective effects of microglia in multiple sclerosis

Review published in Exp Neurol (2009)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewGenomik & ProteomikNapoli I, Neumann H · Experimental neurology, 2009

Abstract

The role of microglia in demyelinating neurodegenerative diseases such as multiple sclerosis (MS) and its animal model experimental autoimmune encephalomyelitis (EAE) is still controversial. Although microglial cells are known as the professional phagocytes and executer of innate immunity in the central nervous system (CNS), it is believed that microglia are rather neurotoxic in these diseases. However, there is recent evidence indicating that microglia could also exert a neuroprotective function in MS and EAE. First evidence for the protective effect of immune cells in CNS diseases emerged from studies in invertebrates. In the medicinal leech, the process of regeneration begins with rapid activation and accumulation of phagocytic glial cells at the lesion site followed by phagocytosis of damaged tissue by these cells which promoted robust neural regeneration. In vertebrates, several lines of evidence demonstrate that microglia are also involved in neuroprotection by the secretion of soluble mediators that trigger neural repair and usually contribute to the creation of an environment conductive for regeneration. The efficient removal of apoptotic cells and clearance of debris at the lesion site and the recruitment of stem cell populations as well as the induction of neurogenesis are directly correlated. These findings suggest that microglia play a major role in creating a microenvironment for repair and regenerative processes in demyelinating neuroinflammatory diseases.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, Non-U.S. Gov'tReview
Indexed MeSH termsAnimalsCell CommunicationCytoprotectionHumansMicrogliaMultiple SclerosisNerve Fibers, MyelinatedNerve Regeneration

Zusammenfassung

Reviews evidence from leech microglia studies and vertebrate models showing that microglia exert neuroprotection by secreting mediators that trigger neural repair, recruit stem cells, and remove apoptotic debris.

Warum dies für die Hirudotherapie relevant ist

This review article discusses the potentially neuroprotective roles of microglia in multiple sclerosis (MS) and its animal model EAE, highlighting evidence that microglia contribute to neuroprotection through secretion of soluble mediators, clearance of debris, and recruitment of stem cells. The abstract notes that early evidence for protective immune cell function in CNS injury came from studies in the medicinal leech, where rapid activation and accumulation of phagocytic glial cells at lesion sites promoted robust neural regeneration. This review is primarily focused on vertebrate neuroimmunology and MS; the leech is mentioned only as a historical comparative model demonstrating glial-mediated repair. The study has no direct relevance to hirudotherapy, the leech secretome, or clinical leech application.

Zitation

Protective effects of microglia in multiple sclerosis.

Napoli I, Neumann H · Experimental neurology, 2009

Verwandter klinischer Kontext

Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist

Zur ASH-Bibliothek hinzugefügt: May 26, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.